|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CMPK2 |
Gene summary for CMPK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CMPK2 | Gene ID | 129607 |
| Gene name | cytidine/uridine monophosphate kinase 2 | |
| Gene Alias | NDK | |
| Cytomap | 2p25.2 | |
| Gene Type | protein-coding | GO ID | GO:0002237 | UniProtAcc | Q5EBM0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 129607 | CMPK2 | LZE24T | Human | Esophagus | ESCC | 1.47e-24 | 7.32e-01 | 0.0596 |
| 129607 | CMPK2 | P2T-E | Human | Esophagus | ESCC | 3.58e-28 | 5.94e-01 | 0.1177 |
| 129607 | CMPK2 | P5T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.23e-01 | 0.1327 |
| 129607 | CMPK2 | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.31e-01 | 0.0889 |
| 129607 | CMPK2 | P9T-E | Human | Esophagus | ESCC | 3.67e-14 | 3.20e-01 | 0.1131 |
| 129607 | CMPK2 | P11T-E | Human | Esophagus | ESCC | 6.74e-09 | 3.63e-01 | 0.1426 |
| 129607 | CMPK2 | P17T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.90e-01 | 0.1278 |
| 129607 | CMPK2 | P20T-E | Human | Esophagus | ESCC | 2.18e-03 | 2.08e-01 | 0.1124 |
| 129607 | CMPK2 | P21T-E | Human | Esophagus | ESCC | 1.96e-05 | 2.65e-01 | 0.1617 |
| 129607 | CMPK2 | P22T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.15e-01 | 0.1236 |
| 129607 | CMPK2 | P23T-E | Human | Esophagus | ESCC | 6.93e-10 | 3.82e-01 | 0.108 |
| 129607 | CMPK2 | P24T-E | Human | Esophagus | ESCC | 1.35e-23 | 5.43e-01 | 0.1287 |
| 129607 | CMPK2 | P27T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.54e-01 | 0.1055 |
| 129607 | CMPK2 | P28T-E | Human | Esophagus | ESCC | 8.08e-19 | 3.78e-01 | 0.1149 |
| 129607 | CMPK2 | P31T-E | Human | Esophagus | ESCC | 6.38e-31 | 6.69e-01 | 0.1251 |
| 129607 | CMPK2 | P36T-E | Human | Esophagus | ESCC | 1.47e-14 | 5.66e-01 | 0.1187 |
| 129607 | CMPK2 | P37T-E | Human | Esophagus | ESCC | 1.87e-02 | 9.24e-02 | 0.1371 |
| 129607 | CMPK2 | P39T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.20e-01 | 0.0894 |
| 129607 | CMPK2 | P40T-E | Human | Esophagus | ESCC | 6.29e-20 | 5.15e-01 | 0.109 |
| 129607 | CMPK2 | P42T-E | Human | Esophagus | ESCC | 3.05e-02 | 1.26e-01 | 0.1175 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009141111 | Esophagus | ESCC | nucleoside triphosphate metabolic process | 78/8552 | 112/18723 | 2.36e-07 | 3.59e-06 | 78 |
| GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
| GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
| GO:000914219 | Esophagus | ESCC | nucleoside triphosphate biosynthetic process | 58/8552 | 85/18723 | 2.16e-05 | 1.87e-04 | 58 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:000913219 | Esophagus | ESCC | nucleoside diphosphate metabolic process | 77/8552 | 124/18723 | 1.65e-04 | 1.09e-03 | 77 |
| GO:000920012 | Esophagus | ESCC | deoxyribonucleoside triphosphate metabolic process | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
| GO:00062203 | Esophagus | ESCC | pyrimidine nucleotide metabolic process | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
| GO:00091473 | Esophagus | ESCC | pyrimidine nucleoside triphosphate metabolic process | 20/8552 | 25/18723 | 4.81e-04 | 2.69e-03 | 20 |
| GO:00091234 | Esophagus | ESCC | nucleoside monophosphate metabolic process | 49/8552 | 76/18723 | 7.30e-04 | 3.80e-03 | 49 |
| GO:000926212 | Esophagus | ESCC | deoxyribonucleotide metabolic process | 31/8552 | 44/18723 | 7.70e-04 | 3.99e-03 | 31 |
| GO:00725273 | Esophagus | ESCC | pyrimidine-containing compound metabolic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
| GO:00092633 | Esophagus | ESCC | deoxyribonucleotide biosynthetic process | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| GO:001969212 | Esophagus | ESCC | deoxyribose phosphate metabolic process | 29/8552 | 42/18723 | 1.87e-03 | 8.46e-03 | 29 |
| GO:004693919 | Esophagus | ESCC | nucleotide phosphorylation | 61/8552 | 101/18723 | 2.03e-03 | 9.08e-03 | 61 |
| GO:00091483 | Esophagus | ESCC | pyrimidine nucleoside triphosphate biosynthetic process | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
| GO:000616519 | Esophagus | ESCC | nucleoside diphosphate phosphorylation | 59/8552 | 99/18723 | 3.65e-03 | 1.49e-02 | 59 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012325 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa002405 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa0123212 | Esophagus | ESCC | Nucleotide metabolism | 59/4205 | 85/8465 | 1.67e-04 | 6.58e-04 | 3.37e-04 | 59 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0024012 | Esophagus | ESCC | Pyrimidine metabolism | 41/4205 | 58/8465 | 9.14e-04 | 2.92e-03 | 1.49e-03 | 41 |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa012324 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa002404 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| hsa0123211 | Oral cavity | OSCC | Nucleotide metabolism | 54/3704 | 85/8465 | 1.78e-04 | 5.95e-04 | 3.03e-04 | 54 |
| hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
| hsa0024011 | Oral cavity | OSCC | Pyrimidine metabolism | 37/3704 | 58/8465 | 1.62e-03 | 4.45e-03 | 2.26e-03 | 37 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CMPK2 | deletion | Frame_Shift_Del | novel | c.770delT | p.Ile257ThrfsTer12 | p.I257Tfs*12 | Q5EBM0 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CMPK2 | SNV | Missense_Mutation | rs527462136 | c.1310C>T | p.Thr437Met | p.T437M | Q5EBM0 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CMPK2 | SNV | Missense_Mutation | rs751941297 | c.721G>A | p.Asp241Asn | p.D241N | Q5EBM0 | protein_coding | deleterious(0.02) | benign(0.328) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CMPK2 | SNV | Missense_Mutation | c.727N>C | p.Cys243Arg | p.C243R | Q5EBM0 | protein_coding | tolerated(0.23) | benign(0.196) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CMPK2 | SNV | Missense_Mutation | novel | c.1004N>A | p.Ser335Asn | p.S335N | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CMPK2 | SNV | Missense_Mutation | c.1134N>A | p.Ser378Arg | p.S378R | Q5EBM0 | protein_coding | deleterious(0.03) | possibly_damaging(0.643) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CMPK2 | SNV | Missense_Mutation | c.911N>T | p.Arg304Ile | p.R304I | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CMPK2 | SNV | Missense_Mutation | novel | c.879N>T | p.Lys293Asn | p.K293N | Q5EBM0 | protein_coding | tolerated(0.1) | benign(0.039) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CMPK2 | SNV | Missense_Mutation | c.1111C>A | p.Leu371Ile | p.L371I | Q5EBM0 | protein_coding | tolerated(0.11) | benign(0.103) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CMPK2 | SNV | Missense_Mutation | c.692C>A | p.Pro231His | p.P231H | Q5EBM0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |